TickerFacts.

Maze Therapeutics, Inc. (MAZE): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$111.94M
Year ended 2025-12-31
-$106.54M
Trailing 12 months to 2026-06-30
$75.95M2024-12-31: $75.95M2025-12-31: -$111.94M-$111.94M
2024-12-31 Operating Cash Flow (USD) 2025-12-31
Period endedOperating Cash FlowChange YoYSource filing
2025-12-31-$111.94Mn/m2026-03-25, From 2025-01-01
2024-12-31$75.95Mn/a2026-03-25, From 2024-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
Maze Therapeutics, Inc. (MAZE)2025-12-31-$111.94Mn/m
Scholar Rock Holding Corp (SRRK)2025-12-31-$300.04Mn/m
Allogene Therapeutics, Inc. (ALLO)2025-12-31-$149.25Mn/m
Sana Biotechnology, Inc. (SANA)2025-12-31-$143.83Mn/m
Scilex Holding Co (SCLX)2025-12-31$3.82M-80.3%
C4 Therapeutics, Inc. (CCCC)2025-12-31-$98.69Mn/m
Cullinan Therapeutics, Inc. (CGEM)2025-12-31-$175.75Mn/m
Kodiak Sciences Inc. (KOD)2025-12-31-$136.01Mn/m
Monte Rosa Therapeutics, Inc. (GLUE)2025-12-31-$22.80Mn/m

Compare MAZE, SRRK, ALLO, SANA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗